Please login to the form below

Not currently logged in
Email:
Password:

COPD asthma

This page shows the latest COPD asthma news and features for those working in and with pharma, biotech and healthcare.

UK biotech Synairgen treats first patient in phase 3 COVID-19 trial

UK biotech Synairgen treats first patient in phase 3 COVID-19 trial

Prior to the COVID-19 pandemic, Synairgen had been evaluating the drug as a treatment for COPD and asthma, although its focus has now shifted to investigating SNG001’s potential in

Latest news

More from news
Approximately 7 fully matching, plus 83 partially matching documents found.

Latest Intelligence

  • AI: the smart money is on the smart thinking AI: the smart money is on the smart thinking

    The software helps differentiate patients from those suffering with similar symptoms that are actually a result of asthma and chronic obstructive pulmonary disease (COPD), and therefore diagnose CTEPH more reliably and

  • A snapshot of… Enterprise Therapeutics A snapshot of… Enterprise Therapeutics

    of infection in respiratory diseases such as cystic fibrosis (CF) and COPD. ... In addition, we have the opportunity to evaluate the clinical efficacy of our drugs in other muco-obstructive lung diseases such as COPD, severe asthma, bronchiectasis and

  • GSK forges ahead with its dynamic COPD and asthma portfolio GSK forges ahead with its dynamic COPD and asthma portfolio

    The emergence of eosinophil counts as a biomarker in COPD has been helpful. ... You would imagine coronavirus would be one of those threats.”. GSK is trialling its biologic anti IL-5 drug mepolizumab, licensed for severe asthma, in eosinophilic COPD

  • AstraZeneca: building a new ‘open innovation’ pharma company AstraZeneca: building a new ‘open innovation’ pharma company

    AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma.

  • The good, the bad and the ugly The good, the bad and the ugly

    Its revenues grew by a further 9% last year. “A large percentage of this growth was driven by Ellipta, but Nucala - a biologic approved for asthma and COPD - also played its ... The category has also seen the recent introduction of a major drug class

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Addressing Climate Impact: The Healthcare Paradox Addressing Climate Impact: The Healthcare Paradox

    Boehringer Ingelheim recently introduced the first reusable, propellant-free inhaler for patients with asthma and COPD, supporting objectives of carbon and plastic waste reduction.

  • RWE Blog 1: Real-world challenges and real-world data

    In  a review of 870 out-patients with asthma and/or Chronic Obstructive Pulmonary Disease (COPD), only one in 20 asthma patients and one in six COPD patients met the typical

  • A Bitter Pill?

    as asthma and COPD, where inhalers are the most effective way to deliver medications to the target, this is particularly relevant because success is so dependent on good technique and some

  • Telehealth Research

    Telehealth services are being used by more and more patients with chronic diseases such as asthma, COPD, diabetes and cardiovascular disease.

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite Digital

Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...

Latest intelligence

PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story
How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
AI healthcare
Three ways AI will change healthcare in the next decade
Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...

Infographics